以α-甲基-l-色氨酸替换l-色氨酸获得177Lu-AMTG:一种高亲和力、体内稳定性改善的胃泌素释放肽受体配体
本研究通过将RM2药效团中代谢不稳定的Gln7-Trp8键中的l-Trp8替换为α-甲基-l-色氨酸,合成177Lu-AMTG及其DOTAGA类似物177Lu-AMTG2,并以177Lu-RM2和177Lu-NeoBOMB1为参照进行临床前比较评价。结果显示177Lu-AMTG在体外和体内稳定性明显改善,注射后24小时肿瘤滞留最高(11.45±0.43%ID/g)、肿瘤/血比值最高(2,702±321),SPECT/CT显示肿瘤组织清除较慢;177Lu-AMTG2未显示进一步优势。作者据此强烈推荐对177Lu-AMTG开展临床评价。
要点
- 将RM2的l-Trp8替换为α-甲基-l-色氨酸得到177Lu-AMTG,其体外和体内稳定性较177Lu-RM2明显改善。
- 注射后24小时177Lu-AMTG肿瘤滞留11.45±0.43%ID/g、肿瘤/血比值2,702±321,均为所比较配体中最高的。
- 177Lu-AMTG2较177Lu-AMTG未显示任何进一步优势。
核心结论
- 作者基于177Lu-AMTG优越的代谢稳定性,强烈推荐对该新型GRPR靶向配体进行临床评价,以探索其用于GRPR表达恶性肿瘤放射配体治疗的潜力。
研究设计与样本
- 临床前比较研究,合成177Lu-AMTG及其DOTAGA类似物177Lu-AMTG2,并以177Lu-RM2和177Lu-NeoBOMB1为参照化合物。
- 肽通过固相肽合成制备并用177Lu标记,在pH 7.4下测定亲脂性(logD 7.4)。
- 在PC-3细胞(37°C、60分钟)研究受体介导的内化,在PC-3和T-47D细胞测定GRPR亲和力(半数抑制浓度)。
- 在体外(人血浆,37°C,72±2小时)和体内(小鼠血浆,注射后30分钟)考察对肽酶的稳定性。
- 注射后24小时进行生物分布研究,并在PC-3荷瘤小鼠注射后1、4、8、24和28小时行小动物SPECT/CT。
主要发现
- 固相肽合成得到9%-15%的纯化标记前体,177Lu标记定量完成。
- 与177Lu-RM2相比,177Lu-AMTG的GRPR亲和力略有改善,内化率相似且低,亲脂性略增,体外和体内稳定性明显改善。
- 注射后24小时177Lu-AMTG肿瘤滞留为11.45±0.43%ID/g、肿瘤/血比值为2,702±321,均为最高,并具有有利的生物分布特征。
- 小动物SPECT/CT显示177Lu-AMTG从肿瘤组织清除较慢。
- 与177Lu-AMTG相比,177Lu-AMTG2未显示任何进一步优势。
关键数值与推荐
- 177Lu-AMTG注射后24小时肿瘤滞留11.45±0.43%ID/g,肿瘤/血比值2,702±321。
- 固相肽合成纯化标记前体产率为9%-15%。
- 体外稳定性在人血浆37°C、72±2小时条件下考察;体内稳定性在小鼠血浆注射后30分钟考察。
临床怎么用
- 作者强烈推荐对177Lu-AMTG开展临床评价,以探索其用于GRPR表达恶性肿瘤放射配体治疗的潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Theranostic applications targeting the gastrin-releasing peptide receptor (GRPR) have shown promising results. When compared with other peptide ligands for radioligand therapy, the most often used GRPR ligand, DOTA-Pip5-d-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2 (RM2), may be clinically impacted by limited metabolic stability. With the aim of improving the metabolic stability of RM2, we investigated whether the metabolically unstable Gln7-Trp8 bond within the pharmacophore of RM2 can be stabilized via substitution of l-Trp8 by α-methyl-l-tryptophan (α-Me-l-Trp) and whether the corresponding DOTAGA analog might also be advantageous. A comparative preclinical evaluation of 177Lu-α-Me-l-Trp8-RM2 (177Lu-AMTG) and its DOTAGA counterpart (177Lu-AMTG2) was performed using 177Lu-RM2 and 177Lu-NeoBOMB1 as reference compounds. Methods: Peptides were synthesized by solid-phase peptide synthesis and labeled with 177Lu. Lipophilicity was determined at pH 7.4 (logD 7.4). Receptor-mediated internalization was investigated on PC-3 cells (37°C, 60 min), whereas GRPR affinity (half-maximal inhibitory concentration) was determined on both PC-3 and T-47D cells. Stability toward peptidases was examined in vitro (human plasma, 37°C, 72 ± 2 h) and in vivo (murine plasma, 30 min after injection). Biodistribution studies were performed at 24 h after injection, and small-animal SPECT/CT was performed on PC-3 tumor-bearing mice at 1, 4, 8, 24, and 28 h after injection. Results: Solid-phase peptide synthesis yielded 9%-15% purified labeling precursors. 177Lu labeling proceeded quantitatively. Compared with 177Lu-RM2, 177Lu-AMTG showed slightly improved GRPR affinity, a similar low internalization rate, slightly increased lipophilicity, and considerably improved stability in vitro and in vivo. In vivo, 177Lu-AMTG exhibited the highest tumor retention (11.45 ± 0.43 percentage injected dose/g) and tumor-to-blood ratio (2,702 ± 321) at 24 h after injection, as well as a favorable biodistribution profile. As demonstrated by small-animal SPECT/CT imaging, 177Lu-AMTG also revealed a less rapid clearance from tumor tissue. Compared with 177Lu-AMTG, 177Lu-AMTG2 did not show any further benefits. Conclusion: The results of this study, particularly the superior metabolic stability of 177Lu-AMTG, strongly recommend a clinical evaluation of this novel GRPR-targeted ligand to investigate its potential for radioligand therapy of GRPR-expressing malignancies.
引用
- Günther T, Deiser S, Felber V, et al. Substitution of l-Tryptophan by α-Methyl-l-Tryptophan in 177Lu-RM2 Results in 177Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo Stability. J Nucl Med. 2022. PMID: 35027371. doi:10.2967/jnumed.121.263323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。